Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Follow-On-Biologics S. 623 and H.R. 1038 – Access to Life-Saving Medicines Act H.R. 1956 – Patient Protection and Innovative Biologic Medicines Act of 2007 S. 1695 - Biologics Price Competition and Innovation Act of 2007 FDA Drug Safety Oversight S.1082 – Prescription Drug User Fee Amendments of 2007 H.R. 2900 – Food and Drug Administration Amendments Act of 2007
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: AMGEN INC · Firm: AMGEN, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AMGEN INC via AMGEN, INC.
2007 · year_end · YY
Intellectual property and process patent issues S. 1145 and H.R.. 1908 Patent Reform Act of 2007
FDA Drug Safety Oversight H.R. 2900, Prescription Drug User Fee Amendments of 2007 H.R. 3580, Food and Drug Administration Amendments Act of 2007 Follow-On-Biologics
Source: Senate LDA
Follow-On-Biologics S. 623 and H.R. 1038 – Access to Life-Saving Medicines Act H.R. 1956 – Patient Protection and Innovative Biologic Medicines Act of 2007 S. 1695 - Biologics Price Competition and Innovation Act of 2007 FDA Drug Safety Oversight S.1082 – Prescription Drug User Fee Amendments of 2007 H.R. 2900 – Food and Drug Administration Amendments Act of 2007
FDA Drug Safety Oversight H.R. 2900, Prescription Drug User Fee Amendments of 2007 H.R. 3580, Food and Drug Administration Amendments Act of 2007 Follow-On-Biologics
Follow-On-Biologics S. 623 and H.R. 1038 – Access to Life-Saving Medicines Act H.R. 1956 – Patient Protection and Innovative Biologic Medicines Act of 2007 S. 1695 - Biologics Price Competition and Innovation Act of 2007 FDA Drug Safety Oversight S.1082 – Prescription Drug User Fee Amendments of 2007 H.R. 2900 – Food and Drug Administration Amendments Act of 2007
FDA Drug Safety Oversight H.R. 2900, Prescription Drug User Fee Amendments of 2007 H.R. 3580, Food and Drug Administration Amendments Act of 2007 Follow-On-Biologics
Intellectual property and process patent issues S. 1145 and H.R.. 1908 Patent Reform Act of 2007
Intellectual property and process patent issues S. 1145 and S. 1908 – Patent Reform Act of 2007
Follow-On-Biologics S. 623 and H.R. 1038 – Access to Life-Saving Medicines Act H.R. 1956 – Patient Protection and Innovative Biologic Medicines Act of 2007 S. 1695 - Biologics Price Competition and Innovation Act of 2007 FDA Drug Safety Oversight S.1082 – Prescription Drug User Fee Amendments of 2007 H.R. 2900 – Food and Drug Administration Amendments Act of 2007
A bill to amend the procedures regarding military recruiter access to secondary school student recruiting information.
Client: AMGEN INC · Firm: AMGEN, INC.
Intellectual property and process patent issues S. 1145 and S. 1908 – Patent Reform Act of 2007
Follow-On-Biologics S. 623 and H.R. 1038 – Access to Life-Saving Medicines Act H.R. 1956 – Patient Protection and Innovative Biologic Medicines Act of 2007 S. 1695 - Biologics Price Competition and Innovation Act of 2007 FDA Drug Safety Oversight S.1082 – Prescription Drug User Fee Amendments of 2007 H.R. 2900 – Food and Drug Administration Amendments Act of 2007
Medicare Coverage and Reimbursement Issues Implementation of H.R. 1 Medicare Prescription Drug & Modernization Act of 2003 Implementation of the Medicaid Drug Rebate Program H.R. 3162, Children's Health and Medicare Protection Act of 2007
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)
AMGEN INC via AMGEN, INC.
2007 · mid_year · MM
Implementation of H.R. 1 Medicare Prescription Drug & Modernization Act of 2003 Medicare coverage and reimbursement of Erythropoiesis-Stimulating Agents Implementation of Medicaid Drug Rebate provisions of the Deficit Reduction Act of 2005
Intellectual property and process patent issues S. 1145 and S. 1908 – Patent Reform Act of 2007
Corporate Tax Issues
Follow-On-Biologics S. 623 and H.R. 1038 – Access to Life-Saving Medicines Act H.R. 1956 – Patient Protection and Innovative Biologic Medicines Act of 2007 S. 1695 - Biologics Price Competition and Innovation Act of 2007 FDA Drug Safety Oversight S.1082 – Prescription Drug User Fee Amendments of 2007 H.R. 2900 – Food and Drug Administration Amendments Act of 2007
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)
AMGEN INC via AMGEN, INC.
2004 · year_end · YY
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMGEN INC via AMGEN, INC.
2003 · year_end · YY
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMGEN INC via AMGEN, INC.
2003 · mid_year · MM
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMGEN INC via AMGEN, INC.
2001 · year_end · YY
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE